April 28, 2020 / 5:07 AM / a month ago

BRIEF-Ptc Therapeutics Says Positive Results From Part 2 Of Pivotal Firefish Study Evaluating Risdiplam In Infants With Type 1 Spinal Muscular Atrophy (SMA)

April 28 (Reuters) - PTC Therapeutics Inc:

* POSITIVE RESULTS FROM PART 2 OF PIVOTAL FIREFISH STUDY EVALUATING RISDIPLAM IN INFANTS WITH TYPE 1 SPINAL MUSCULAR ATROPHY (SMA)

* MEANINGFUL BENEFIT OBSERVED IN DOSE-FINDING PART 1 CONFIRMED; PDUFA EXPECTED AUGUST 24, 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below